产品
编 号：F741732
分子式：C24H19ClN6O
分子量：442.9
分子式：C24H19ClN6O
分子量：442.9
产品类型
规格
价格
是否有货
10mM*1mL in DMSO
询价
询价
5mg
询价
询价
10mg
询价
询价
25mg
询价
询价
50mg
询价
询价
结构图
CAS No: 2708934-53-4
产品详情
生物活性：
CCF0058981 (CCF981), 3-chlorophenyl analogue, is a noncovalent SARS-CoV-2 3CLpro (SC2) inhibitor with an IC50 of 68 nM. CCF0058981 inhibits SC1 (SARS-CoV-1 3CLpro) with an IC50 of 19 nM. CCF0058981 has antiviral efficacy and has the potential for COVID-19 research.
体外研究：
CCF0058981 (CCF981) has cytopathic effect (CPE) inhibition (EC50=497 nM) and plaque reduction (EC50=558 nM) in vitro viral replication. CCF0058981 has the 50% cytotoxic concentration (CC50) in the CPE antiviral assay of >50 μM. CCF0058981 has a T1/2 of 21.1 min, a CLlnt of 141 mL/min?kg in Human liver microsomes.
CCF0058981 (CCF981), 3-chlorophenyl analogue, is a noncovalent SARS-CoV-2 3CLpro (SC2) inhibitor with an IC50 of 68 nM. CCF0058981 inhibits SC1 (SARS-CoV-1 3CLpro) with an IC50 of 19 nM. CCF0058981 has antiviral efficacy and has the potential for COVID-19 research.
体外研究：
CCF0058981 (CCF981) has cytopathic effect (CPE) inhibition (EC50=497 nM) and plaque reduction (EC50=558 nM) in vitro viral replication. CCF0058981 has the 50% cytotoxic concentration (CC50) in the CPE antiviral assay of >50 μM. CCF0058981 has a T1/2 of 21.1 min, a CLlnt of 141 mL/min?kg in Human liver microsomes.
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备